Tiludronate in horses: Tolerance and short-term effects on bone metabolism;Tiludronate chez le cheval: Tolérance et effets à court terme sur le métabolisme osseux

Annales de Medecine Veterinaire

Volumn 146, Issue 2, 2002, Pages 123-130

  Varela, A ^a,b   Lepage, O M ^a   Doucet, M ^b   Marcoux, M ^b   Garnero, P ^c  

^a VETAGRO SUP   (France)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOCHEMICAL MARKER; CALCIUM; COLLAGEN TYPE 1; CREATININE; MATRIX METALLOPROTEINASE; OSTEOCALCIN; PEPTIDE DERIVATIVE; TILUDRONIC ACID;

ANIMAL EXPERIMENT; ARTICLE; BIOCHEMISTRY; BIOLOGICAL MONITORING; BONE METABOLISM; CALCIUM BLOOD LEVEL; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG TOLERANCE; HEART ARRHYTHMIA; HEART RATE; HORSE; HYPOCALCEMIA; KIDNEY; LIVER; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PARAMETER; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; PROTEIN CROSS LINKING; PROTEIN DETERMINATION;

ANIMALIA; EQUIDAE; EQUUS CABALLUS;

EID: 0036017439     PISSN: 00034118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Effects of the bisphosphonate tiludronate on bone resorption, calcium balance and bone density
2. Treatment of Paget's disease of bone with (4-chloro-phenyl) thiomethylene bisphosphonate
3. 245 Fractures in Thouroughbred racehorses: Results of a 2 year prospective study in Newmarket
4. Diurnal variation and age differences in biochemical markers of bone turnover in horses
5. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease
6. Tiludronate: Bone pharmacology and safety
7. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides
8. The use of biochemical markers of bone turnover in osteoporosis
9. Increased bone formation in osteocalcin-deficient mice
10. High-speed exercise history and catastrophic racing fracture in thoroughbreds
11. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy
12. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease
13. Assessment of the serum levels of bone alkaline phosphatase with a new direct immunoradiometric assay in patients with metabolic bone disease
14. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease
15. Biochemical markers of bone turnover. Applications for osteoporosis
16. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis
17. New bisphosphonates in the treatment of bone diseases
18. The effects of exercise on biochemical markers of bone metabolisme in the horse
19. Measurement of bone specific alkaline phosphatase in horse: A comparison of two techniques
20. An assessment of wastage in thoroughbred racing from conception to 4 years of age
21. Assessment of bone resorption marker assays in Thoroughbred horses
22. Aspects microradiographiques et en microscopie de fluorescence d'une exostose expérimentale du métacarpien chez le poney Shetland et de son traitemem par un bisphosphonate, l'AHPrBP (APD). Applications possibles au cheval d'arme
23. Serum osteocalcin or bone Gla-protein, a biochemical marker for bone metabolism in horses: Differences in serum levels with age
24. Circadian rythms of osteocalcin in equine serum. Correlation with alkaline phosphatase, calcium, phosphate and total protein levels
25. Serum osteocalcin concentration in horses treated with triamcinolone acetonide
26. Modelage er remaniement osseux. Observations sur les os métacarpiens du poney Shetland
27. Biochemical markers of bone metabolism in draught and warmblood horses
28. Non-invasive assessment of equine bone: An update
29. A double-blind placebo-controlled trial of bisphosphonate in the treatment of navicular syndrome
30. A specific radioimmunoassay for osteocalcin with advantageous species crossreactivity
31. Career profile of the Canadian Standardbred. III. Influence of temporary absence from racing and season
32. Age related changes in biochemical markers of bone metabolism in horses
33. Serum levels of molecular markers in growing horses: The effects of age, season and orthopaedic disease
34. Prevention of postmenopausal bone loss by tiludronate
35. Implications of bone adaptation in the thoroughbred racehorse
36. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen
37. Calcium-regulating hormones and diseases of abnormal mineral metabolism
38. Epidemiological study of wastage among racehorses 1982 and 1983
39. Human pharmacokinetics of tiludronate
40. Stress fractures
41. Biochemical markers of bone turnover for the clinical assessment of bone metabolism
42. Hypocalcemia in horses